Phase I-II clinical trial of Californium-252. Treatment of stage IB carcinoma of the cervix

Journal Article · Wed Apr 15 04:00:00 EDT 1987 · Cancer (Philadelphia); (United States)

DOI:https://doi.org/10.1002/1097-0142(19870415)59:8<1500::AID-CNCR2820590818>3.0.CO;2-9· OSTI ID:6591813

Maruyama, Y; VanNagell, J R; Yoneda, J; Donaldson, E; Gallion, H; Rowley, K; Kryscio, R; Beach, J L

Intracavitary Californium-252 combined with whole-pelvis photon radiotherapy was tested as the sole form of treatment for 22 patients with Stage IB carcinoma of the cervix. Californium-252 (Cf) is a fast neutron-emitting radioisotope currently being tested in trials of neutron brachytherapy (NT). The outcomes of the treated group of patients were traced for local tumor control, survival, patterns of failure, and complications. The Cf intracavitary therapy combined with whole-pelvis photon radiotherapy resulted in 95% 2-year and 91% 5-year actuarial survival. There were 9% Grade II-III complications by the Stockholm scale and 4% local failures. These results were obtained in an early clinical trial with a group of largely poor-risk patients with tumors of mean diameter of 4.3 cm.

• Research Organization: Univ. of Kentucky Medical Center, Lexington
• OSTI ID: 6591813
• Journal Information: Cancer (Philadelphia); (United States), Journal Name: Cancer (Philadelphia); (United States) Vol. 8; ISSN CANCA
• Country of Publication: United States
• Language: English

Related Subjects

550603* -- Medicine-- External Radiation in Therapy-- (1980-)
62 RADIOLOGY AND NUCLEAR MEDICINE
ACTINIDE ISOTOPES
ACTINIDE NUCLEI
ALPHA DECAY RADIOISOTOPES
BARYONS
BODY
BODY AREAS
CALIFORNIUM 252
CALIFORNIUM ISOTOPES
CARCINOMAS
DISEASES
ELEMENTARY PARTICLES
EVEN-EVEN NUCLEI
FAST NEUTRONS
FEMALE GENITALS
FERMIONS
HADRONS
HEAVY NUCLEI
ISOTOPES
MEDICINE
NEOPLASMS
NEUTRONS
NUCLEAR MEDICINE
NUCLEI
NUCLEONS
ORGANS
PATIENTS
PELVIS
RADIOISOTOPES
RADIOLOGY
RADIOTHERAPY
THERAPY
UTERUS
YEARS LIVING RADIOISOTOPES